Regarding the issue of "the company's future industrial investment direction," Sanxin Medtec stated during an institutional research on April 3 that the company continues to focus on its main business, innovating and upgrading blood dialysis products, improving continuous renal replacement therapy (CRRT), and various blood purification treatment model product groups. Additionally, the company is laying out a comprehensive management strategy for kidney diseases, including diabetes, early to mid-stage kidney disease, and vascular intervention. At the same time, the company is actively monitoring external projects and will further increase its exploration of existing tracks and new fields